Instituto de Medicina Integral Professor Fernando Figueira (IMIP)
Recife, Pernambuco, 50070-550, Brazil
NCT Number: NCT01406392
The purpose of this study is to compare effectiveness and safety of a sublingual misoprostol 12,5 mcg with vaginal misoprostol 25 mcg for induction of labour with an alive and term fetus.
Looking for future studies?
Notify MeSeveral methods for induction of labour are available. However, the most effective and with less frequency of adverse effects is still unknown. Vaginal misoprostol has been used frequently to induce labour but other routes of administrations have been proposed, such as oral and sublingual. The purpose of this study is to compare effectiveness and safety of sublingual misoprostol 12,5 mcg with vaginal misoprostol 25 mcg administration for induction of labour with an alive and term fetus. A randomized controlled double-blind trial will be carried in two hospitals: Instituto de Medicina Integral Prof. Fernando Figueira and Universidade Federal do Ceará and Instituto de Saúde Elpídio de Almeida, from July 2014 to November 2016. A total of 150 patients must be enrolled. Inclusion criteria are: a) indication for labour induction; b) term pregnancy with alive fetus; Bishop score less than six. Exclusion criteria are: a) previous uterine scar; b) nonvertex presentation; c) non-reassuring fetal status; d) fetal anomalies; e) fetal growth restriction; f) genital bleeding; g) tumors, malformations and/or ulcers of vulva, perineum or vagina. They will be randomized to receive a sublingual misoprostol 12,5 mcg with vaginal placebo tablet or sublingual placebo with vaginal misoprostol 25 mcg tablet. Vaginal tablets will have 25mcg of misoprostol or placebo. Sublingual tablet will have 12,5mcg or placebo. Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Primary outcome will be the frequency of tachysystole. Secondary outcomes will be vaginal delivery within 24 hours, hyperstimulation syndrome, cesarean section, severe neonatal morbidity or perinatal death, serious maternal morbidity or maternal death, need of oxytocin for augmentation of labour, number of misoprostol doses needed to bring on labour, interval from first dose to labour and first dose to delivery, failed induction, uterine rupture, need of labour analgesia, instrumental delivery, side effects, maternal death, meconium, non-reassuring fetal heart rate, Apgar scores less than seven at 1st and 5th minutes, admission at neonatal intensive care unit, neonatal encephalopaty, perinatal death and women not satisfied.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
Other names: Prostokos Cytotec
Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
Other names: Prostokos, Cytotec
Time frame: 48 hours
during 48 hours the presence of taquissistoly will be observed
Time frame: 48 hours
during 48 hours the presence of hyperstimulation syndrome will be observed
Time frame: 12 and 24 hours
changes in the cervix
Time frame: 12 and 24 hours
failure to achieve vaginal delivery
Time frame: after 48 hours
Ask to mother what route of administratios was the best for her
Time frame: after 48 hours
to avaluete the time between the first dose and the onset of labour and delivery
Time frame: after 48 hours
to avaluete the time of duration of labour
Time frame: after 48 hours
to avaluete the use of oxytocin during the labour
Time frame: after 48 hours
to avaluete the faliled induction of labor
Time frame: after 48 hours
to avaluete the number of Caesarean section and the indications for this procedure
Time frame: after 48 hours
to avaluete the need for epidural anaesthesia
Time frame: after 48 hours
to avaluete if occurred any case of maternal side effects (nausea, vomiting, diarrhoea, postpartum haemorrhage and fever);
Time frame: 48 hours
to avaluete severe maternal morbidity (uterine rupture, sepsis and admission to intensive care unit) or maternal death
Time frame: 48 hours
to avaluete meconium in the amniotic fluid
Time frame: 48 hours
non-reassuring foetal heart rate
Time frame: after 48 hours
to avaluete one- and five-minute Apgar scores <7
Time frame: after 48 hours
to avaluete admission of the newborn to a neonatal intensive care unit
Time frame: after 48 hours
to avaluete the need for neonatal resuscitation
Time frame: after 48 hours
to avaluete severe neonatal morbidity (convulsions and neonatal asphyxiation) or perinatal death.
Professor Fernando Figueira Integral Medicine Institute
Other
Sublingual Misoprostol 12,5 mcg Versus Vaginal Misoprostol 25 mcg for Induction of Labour of Alive and Term Fetus : Randomized Controlled Trial
Acronym: SUBMISO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07571785
Childbirth, Labor
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07416487
Labor
Dera Ghazi Khan, Punjab Province, Pakistan
View Trial DetailsNCT05335681
First Stage of Labor, Labor
Karabük, Turkey (Türkiye)
View Trial DetailsNCT07184099
Labor
Attock, Punjab Province, Pakistan
View Trial Details